| 1 | CD55, CD97
|
| Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma.
|
| Wu J, Lei L, Wang S, Gu D, Zhang J.
|
| J Biomed Biotechnol 2012:587672. Epub 2012 Apr 3.
2012
|
| 2 | CD46, CD55, CD59, LAMTOR5
|
| HBXIP upregulates CD46, CD55 and CD59 through ERK1/2/NF-κB signaling to protect breast cancer cells from complement attack.
|
| Cui W, Zhao Y, Shan C, Kong G, Hu N, Zhang Y, Zhang S, Zhang W, Zhang Y, Zhang X, Ye L.
|
| FEBS Lett 586(6):766-71. Epub 2012 Jan 27. 2012
|
| 3 | CD55, CD59
|
| DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.
|
| Soltys J, Halperin JA, Xuebin Q.
|
| J Neuroimmunol 244(1-2):63-9. Epub 2012 Feb 10.
2012
|
| 4 | CD55, CD97
|
| A novel role for CD55 in granulocyte homeostasis and anti-bacterial host defense.
|
| Veninga H, Hoek RM, de Vos AF, de Bruin AM, An FQ, van der Poll T, van Lier RA, Medof ME, Hamann J.
|
| PLoS One 6(10):e24431. Epub 2011 Oct 3.
2011
|
| 5 | CD55, CD97
|
| The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.
|
| Han SL, Xu C, Wu XL, Li JL, Liu Z, Zeng QQ.
|
| Int J Colorectal Dis 25(6):695-702. Epub 2010 Mar 26.
2010
|
| 6 | CD55, CD59
|
| Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients.
|
| Alegretti AP, Mucenic T, Merzoni J, Faulhaber GA, Silla LM, Xavier RM.
|
| Cell Immunol 265(2):127-32. Epub 2010 Aug 2.
2010
|
| 7 | CD55, CD59
|
| Quantitation of CD55 and CD59 expression on reticulocytes and mature erythrocytes in paroxysmal nocturnal hemoglobinuria, aplastic anemia, and healthy control subjects.
|
| Kim Y, Lim J, Kim M, Kim Y, Lee JW, Han K.
|
| Ann Clin Lab Sci 40(3):226-32. 2010
|
| 8 | CD55
|
| Identification of DAF1/CD55, a novel definitive endoderm marker.
|
| Shiraki N, Harada S, Ogaki S, Kume K, Kume S.
|
| Cell Struct Funct 35(2):73-80. Epub 2010 Jun 4.
2010
|
| 9 | CD55, CD59
|
| Decreased expression of complement regulatory proteins, CD55 and CD59, on peripheral blood leucocytes in patients with type 2 diabetes and macrovascular diseases.
|
| Ma XW, Chang ZW, Qin MZ, Sun Y, Huang HL, He Y.
|
| Chin Med J (Engl) 122(18):2123-8.
2009
|
| 10 | CD55
|
| Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.
|
| Li Q, Huang D, Nacion K, Bu H, Lin F.
|
| Mol Immunol 46(15):2885-91. Epub 2009 Aug 5.
2009
|
| 11 | CD55
|
| Preterm labor: CD55 in maternal blood leukocytes.
|
| Nowicki S, Izban MG, Pawelczyk E, Agboto VK, Pratap S, Olson G, Nowicki B.
|
| Am J Reprod Immunol 61(5):360-7.
2009
|
| 12 | CD55
|
| Isolating human islets of Langerhans causes loss of decay accelerating factor (CD55) on beta-cells.
|
| Tai JH, Sun H, Liu W, Melling CW, Hasilo C, White DJ.
|
| Cell Transplant 17(12):1349-59.
2008
|
| 13 | CD55
|
| Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
|
| Harris CL, Pettigrew DM, Lea SM, Morgan BP.
|
| J Immunol 178(1):352-9. 2007
|
| 14 | CD55
|
| Molecular cloning and characterization of novel splicing variants of human decay-accelerating factor.
|
| Osuka F, Endo Y, Higuchi M, Suzuki H, Shio Y, Fujiu K, Kanno R, Oishi A, Terashima M, Fujita T, Gotoh M.
|
| Genomics 88(3):316-22. Epub 2006 Feb 28. 2006
|
| 15 | CD55
|
| Costimulation via CD55 on human CD4+ T cells mediated by CD97.
|
| Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I.
|
| J Immunol 177(2):1070-7. 2006
|
| 16 | CD55, FGF2, VEGFA
|
| bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction.
|
| Mason JC, Lidington EA, Ahmad SR, Haskard DO.
|
| Am J Physiol Cell Physiol 282(3):C578-87. 2002
|
| 17 | CBGI, CD55
|
| Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.
|
| Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME.
|
| J Clin Invest 110(9):1269-74. 2002
|
| 18 | CBGI, CD55
|
| CD55 is over-expressed in the tumour environment.
|
| Li L, Spendlove I, Morgan J, Durrant LG.
|
| Br J Cancer 84(1):80-6. 2001
|
| 19 | CD59, CD55, CD46
|
| Transforming growth factor-beta isoforms regulate the surface expression on membrane cofactor protein (CD46) and CD59 on human keratinocytes.
|
| Pasch MC, et al.
|
| Eur J Immunol 29(1):100-8. 1999
|
| 20 | CD55
|
| Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group inab phenotype.
|
| Wang L, Uchikawa M, Tsuneyama H, Tokunaga K, Tadokoro K, Juji T.
|
| Blood 91(2):680-4. 1998
|
| 21 | CD46, CD46P, CD55, CR1L, RCA@
|
| Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs).
|
| Hourcade D, et al.
|
| Genomics 12 : 289-300. 1992
|
| 22 | CD55, RCA@
|
| Exclusion of unassigned blood group system loci from the regulator of complement activation gene cluster on chromosome 1q32.
|
| Lewis M, et al.
|
| Vox Sang 57 : 210-212. 1989
|
| 23 | CD55, RCA@
|
| The gene encoding decay-accelerating factor (DAF) is located in the complement regulatory locus on the long arm of chromosome 1.
|
| Lemons RS, et al.
|
| (HGM9) Cytogenet Cell Genet 46 : 646. 1987
|
| 24 | CD55, RCA@
|
| Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.
|
| Medof ME, et al.
|
| Proc Natl Acad Sci U S A 84 : 2007-2011. 1987
|